---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-053473"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:20:00.543651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances

## Summary
- Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.
- R&D expenses fell to $64.6M (FY2024) from $117.6M; focus on lead program SER-155.
- Cash $30.8M at Dec 31; plus $50M received Jan 2025, expects funding into Q1 2026.
- SER-155: FDA supports BSI reduction at day 30 as Phase 2 endpoint; draft protocol in Q2 2025.
- Expecting $25M Nestlé installment in July 2025; VOWST sale yields up to $275M in milestones.

## SEC filing metadata
- accession: 0001193125-25-053473
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/0001193125-25-053473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-053473
- JSON: https://secwatch.observer/filing/0001193125-25-053473.json
- Plain text: https://secwatch.observer/filing/0001193125-25-053473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.